{"denoms":[{"counts":[{"groupId":"BG000","value":"130"}],"units":"Participants"}],"groups":[{"description":"Participants received fentanyl sublingual spray 7 times or placebo 3 times in random order to treat up to a maximum of 2 breakthrough pain episodes per day with a minimum separation of 2 hours between treatments. Patients received a dose of 100 to 1600 µg determined in the open-label dose titration period of the current study.","id":"BG000","title":"Fentanyl Sublingual Spray"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"12.2","value":"55.6"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"69"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"61"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}]}